Baltimore, USA - 01 Sep `17Early Molecular Changes After NB-UVB

Official Title: Early Molecular Changes in Vitiligo After Narrowband Ultraviolet Therapy

In Brief: This is an investigator-initiated, single-blinded, ascending dose study of NB-UVB treatment for vitiligo in adults of 3 treatments for one week. It is designed to measure the molecular changes and re-pigmentation in affected and normal skin of participants with vitiligo and normal skin in healthy participants. Participants diagnosed with vitiligo who are enrolled in the study will receive phototherapy (NB-UVB), with the starting dose of 250 mJ/cm2. The dose will be increased by 10% with each treatment. Small skin samples will be collected before and after NB-UVB treatment.

Ages Eligible: 18 Years to 100 Years

Start Date: September 1, 2017 

Completion Date (estimated): September 1, 2022

Status: Active, recruiting

Study ID from ClinicalTrials.gov: NCT03270241

Location: Johns Hopkins Outpatient Center, Baltimore, Maryland, United States, 21287

Contact: To learn more about this study, you or your doctor may contact Ruizhi Wang by phone +1-410-502-7546 or email CTReP@jhmi.edu. Please refer to this study by its NCT number.